Eli Lilly and Company, D-Wave Quantum, Abbott Laboratories, Thermo Fisher Scientific, Merck & Co., Inc., AbbVie, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks represent equity shares of publicly traded companies that research, develop, manufacture and market medications and medical therapies. Investors buy these stocks to gain exposure to the pharmaceutical industry’s growth potential—driven by drug approvals, patent protections and healthcare trends—while bearing risks from regulatory reviews, patent expirations and competitive pressures. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE LLY traded down $7.21 on Monday, hitting $764.50. 1,871,742 shares of the company's stock were exchanged, compared to its average volume of 3,657,523. The stock has a market cap of $724.55 billion, a price-to-earnings ratio of 62.22, a P/E/G ratio of 1.12 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The stock has a 50-day moving average of $767.03 and a 200-day moving average of $800.17.
Read Our Latest Research Report on LLY
D-Wave Quantum (QBTS)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.
D-Wave Quantum stock traded up $0.29 during mid-day trading on Monday, reaching $19.18. The company had a trading volume of 66,194,025 shares, compared to its average volume of 49,783,764. The company has a market cap of $5.60 billion, a P/E ratio of -32.21 and a beta of 1.40. D-Wave Quantum has a fifty-two week low of $0.75 and a fifty-two week high of $20.54. The company has a current ratio of 20.73, a quick ratio of 20.61 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $15.84 and a 200 day simple moving average of $9.97.
Read Our Latest Research Report on QBTS
Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Shares of ABT stock traded up $0.75 during mid-day trading on Monday, reaching $124.42. 6,483,781 shares of the stock traded hands, compared to its average volume of 6,227,464. The stock's fifty day simple moving average is $132.98 and its two-hundred day simple moving average is $129.68. Abbott Laboratories has a 1-year low of $99.92 and a 1-year high of $141.23. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.26. The company has a market cap of $216.47 billion, a price-to-earnings ratio of 15.60, a price-to-earnings-growth ratio of 2.35 and a beta of 0.73.
Read Our Latest Research Report on ABT
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE TMO traded down $3.65 on Monday, hitting $411.11. The company's stock had a trading volume of 1,378,968 shares, compared to its average volume of 2,020,717. The firm has a market cap of $155.19 billion, a PE ratio of 24.08, a PEG ratio of 2.21 and a beta of 0.77. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88. The company's 50-day moving average is $410.38 and its 200 day moving average is $472.32. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.
Read Our Latest Research Report on TMO
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
MRK stock traded down $0.42 during trading on Monday, hitting $79.54. The company had a trading volume of 6,157,832 shares, compared to its average volume of 13,475,264. The stock has a market cap of $199.73 billion, a PE ratio of 11.57, a PEG ratio of 0.83 and a beta of 0.39. The business has a 50-day moving average of $79.37 and a 200-day moving average of $85.70. The company has a current ratio of 1.41, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $128.73.
Read Our Latest Research Report on MRK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of ABBV traded down $3.29 during trading hours on Monday, hitting $185.97. 2,406,047 shares of the stock were exchanged, compared to its average volume of 6,311,495. AbbVie has a fifty-two week low of $163.81 and a fifty-two week high of $218.66. The business has a 50-day moving average of $187.17 and a 200-day moving average of $189.53. The firm has a market capitalization of $328.50 billion, a P/E ratio of 79.16, a price-to-earnings-growth ratio of 1.25 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64.
Read Our Latest Research Report on ABBV
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of NYSE:PFE traded up $0.01 during midday trading on Monday, reaching $24.48. The company's stock had a trading volume of 18,192,607 shares, compared to its average volume of 41,868,877. The firm has a market capitalization of $139.15 billion, a price-to-earnings ratio of 17.72, a PEG ratio of 0.89 and a beta of 0.58. Pfizer has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The firm has a 50 day moving average price of $24.07 and a two-hundred day moving average price of $24.71. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.
Read Our Latest Research Report on PFE
See Also
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
